Thus, suppressing TGF-β pathways in PDAC can lead to attenuated angiogenesis and enhanced cancer directed immune activity by attenuating GM-CSF expression and by suppressing the direct actions of TGF-β on immune cells. The gene discussed is CSF2; the disease is cancer.